

Peer Review

Review of: "A Novel Bispecific Antibody CVL006 Superior to AK112 for Dual Targeting of PD-L1 and VEGF in Cancer Therapy"

Yukinori Endo¹

1. Independent researcher

Therapeutic bispecific monoclonal antibodies are a promising emerging technology for cancer treatment. In this study, the authors have developed a new bispecific antibody, CVL006, targeting PD-L1 and VEGF in V(L)-IgG format, which is different from AK112 in IgG(H)-scFv format. The authors demonstrate in the manuscript that CVL006 is superior to AK112. This study is very interesting.

Minor point: In Figure 2, in the presence of VEGF, CVL006 had higher affinity to PD-L1. This is one of the important and interesting pieces of data in this manuscript.

1. Please include AK112 in the figure to demonstrate the specificity.
2. The results should be discussed in the Discussion section.

Declarations

Potential competing interests: No potential competing interests to declare.